Edition:
United States

Denali Therapeutics Inc (DNLI.OQ)

DNLI.OQ on NASDAQ Stock Exchange Global Select Market

20.49USD
18 Sep 2018
Change (% chg)

-- (--)
Prev Close
$20.49
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
139,779
52-wk High
$25.50
52-wk Low
$12.36

Chart for

About

Denali Therapeutics Inc. is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and others. The Company is developing a diversified portfolio of therapeuti... (more)

Overall

Beta: --
Market Cap(Mil.): $1,942.60
Shares Outstanding(Mil.): 94.81
Dividend: --
Yield (%): --

Financials

  DNLI.OQ Industry Sector
P/E (TTM): -- 108.51 32.45
EPS (TTM): -1.34 -- --
ROI: -32.33 1.61 12.63
ROE: -69.39 0.35 14.80

BRIEF-Denali Therapeutics Reports Q1 Loss Of $0.26 Per Share

* DENALI THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 11 2018

BRIEF-Denali Therapeutics Reports Qtrly Net Loss Per Share $0.74

* DENALI THERAPEUTICS ANNOUNCES FIRST-IN-HUMAN DOSING OF ITS RIPK1 INHIBITOR CLINICAL PROGRAM AND THE APPOINTMENT OF PETER KLEIN TO BOARD OF DIRECTORS; REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

Mar 19 2018

Earnings vs. Estimates